Menu

1 / 34

Why Is Insmed Stock Skyrocketing Thursday? - Sanofi (NASDAQ:SNY), Insmed (NASDAQ:INSM)

Top Stories Feed·Vandana Singh·about 4 hours ago
#bsvr2Jsi
#benzinga#sanofi#insmed#potential#arikayce
Long article (715 words) — no AI summary yet.
Reading 0:00
15s threshold

With Dupixent's Patent Clock Ticking, Sanofi Circles Insmed

Vandana SinghBenzinga Staff Writer November 19, 2026, 1:57 PM ETNov 19, 1:57 PM ET3 min read3 min

SNYSanofi SA

$46.15-2.07%

Stock Score Locked: Want to See it?

Benzinga Edge Rankings give you vital metrics on any stock – anytime.

Reveal Full Score Edge Rankings

MomentumN/A

Growth10.18

Quality18.70

Value34.44

Price Trend

ShortMediumLongOverview INSMInsmed Inc

$141.9718.5%

Insmed Inc. (NASDAQ:INSM) stock surged Thursday following a report that French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is exploring a potential acquisition of the respiratory disease specialist.

The potential acquisition comes as Sanofi seeks new growth opportunities to reduce its reliance on blockbuster drug Dupixent.

Sanofi Explores Potential Insmed Takeover

Bloomberg reported Thursday that Sanofi is considering acquiring Insmed as it searches for its next blockbuster treatment under new CEO Belén Garijo .

Citing people familiar with the matter, the report…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.